Cargando…

Health‐related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non‐interventional study (NIS)

INTRODUCTION: Real‐world data (RWD) on health‐related outcomes in persons with haemophilia A (PwHA) provide insights into patient needs and can guide clinical study design. A global, prospective, non‐interventional study (NIS; NCT02476942) collected detailed RWD on bleeding outcomes, health‐related...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mahlangu, Johnny, Oldenburg, Johannes, Callaghan, Michael U., Shima, Midori, Mancuso, Maria Elisa, Trask, Peter, Recht, Michael, Garcia, Claudia, Yang, Renchi, Lehle, Michaela, Macharia, Harrison, Asikanius, Elina, Levy, Gallia G., Kruse‐Jarres, Rebecca, von Mackensen, Sylvia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850115/ https://www.ncbi.nlm.nih.gov/pubmed/31016855 http://dx.doi.org/10.1111/hae.13731

Ejemplares similares

Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1–3
por: Callaghan, Michael U., et al.
Publicado: (2022)

Health‐related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors—Results from the HAVEN 2 study
por: Mancuso, Maria Elisa, et al.
Publicado: (2020)

The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies
por: Skinner, Mark W., et al.
Publicado: (2021)

Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies
por: Parnes, Aric, et al.
Publicado: (2021)

Progress in the Development of Anti-tissue Factor Pathway Inhibitors for Haemophilia Management
por: Mahlangu, Johnny N.
Publicado: (2021)

Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors
por: Kempton, Christine, et al.
Publicado: (2021)

Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company
por: Hay, Charles R. M., et al.
Publicado: (2020)

Application of a hemophilia mortality framework to the Emicizumab Global Safety Database
por: Peyvandi, Flora, et al.
Publicado: (2020)

Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B
por: Mahlangu, Johnny N.
Publicado: (2018)

Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B
por: Mahlangu, Johnny, et al.
Publicado: (2021)

Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis
por: Pipe, Steven W., et al.
Publicado: (2023)

Emicizumab dose up‐titration in case of suboptimal bleeding control in people with haemophilia A
por: Schmitt, Christophe, et al.
Publicado: (2022)

Assessing patient and caregiver preferences for treatment of haemophilia A: A discrete choice experiment
por: Benton, Melody, et al.
Publicado: (2020)

Health‐related quality of life in paediatric haemophilia B patients treated with rIX‐FP
por: von Mackensen, Sylvia, et al.
Publicado: (2018)

The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors
por: Escobar, Miguel, et al.
Publicado: (2021)

Content comparison of haemophilia specific patient-rated outcome measures with the international classification of functioning, disability and health (ICF, ICF-CY)
por: Riva, Silvia, et al.
Publicado: (2010)

Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study
por: Nolan, Beatrice, et al.
Publicado: (2020)

Achieving the unimaginable: Health equity in haemophilia
por: Skinner, Mark W., et al.
Publicado: (2019)

Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study
por: Kiialainen, Anna, et al.
Publicado: (2022)

Managing NFS and NIS /
por: Stern, Hal
Publicado: (1992)

Managing NFS and NIS
por: Eisler, Mike, et al.
Publicado: (2001)

BAY 81‐8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years
por: Mahlangu, Johnny, et al.
Publicado: (2020)

Clinical utility and impact of the use of the chromogenic vs one‐stage factor activity assays in haemophilia A and B
por: Marlar, Richard A., et al.
Publicado: (2019)

Long‐term safety and efficacy of the anti‐tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results
por: Mahlangu, Johnny, et al.
Publicado: (2022)

Measurement of joint health in persons with haemophilia: A systematic review of the measurement properties of haemophilia‐specific instruments
por: Gouw, Samantha C., et al.
Publicado: (2018)

A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia
por: Mahlangu, Johnny N., et al.
Publicado: (2022)

RNA sequencing suggests that non‐coding RNAs play a role in the development of acquired haemophilia
por: Tigu, Adrian Bogdan, et al.
Publicado: (2023)

Recombinant factor VIII Fc for the treatment of haemophilia A
por: Hermans, Cedric, et al.
Publicado: (2021)

Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors
por: Pipe, Steven W., et al.
Publicado: (2022)

Hæmophilia
Publicado: (1905)

Hæmophilia
por: Ruggles, S. D.
Publicado: (1902)

Hæmophilia
por: Porter, Charles A.
Publicado: (1900)

BAY 81‐8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study
por: Santoro, Cristina, et al.
Publicado: (2020)

Non-Enzymatic Glucose Detection Based on NiS Nanoclusters@NiS Nanosphere in Human Serum and Urine
por: Arivazhagan, Mani, et al.
Publicado: (2021)

Comparison of joint status using ultrasound assessments and Haemophilia Joint Health Score 2.1 in children with haemophilia
por: Li, Yanju, et al.
Publicado: (2023)

The Role of Physiotherapy in the New Treatment Landscape for Haemophilia
por: Lobet, Sébastien, et al.
Publicado: (2021)

Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study
por: Kenet, Gili, et al.
Publicado: (2021)

Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A
por: Auerswald, Guenter, et al.
Publicado: (2012)

Safety of intramuscular COVID‐19 vaccination in patients with haemophilia
por: Tiede, Andreas, et al.
Publicado: (2022)

High adherence to prophylaxis regimens in haemophilia B patients receiving rIX‐FP: Evidence from clinical trials and real‐world practice
por: Mancuso, Maria Elisa, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_542qgg7hl3k24h57vmfenpe4n3